Drug-Coated Stent Prevents Restenosis

Article

NEW YORK -New research shows stents coated with the antibiotic sirolimus are more effective in preventing restenosis - the renarrowing of blood vessels after an angioplasty.

The RAVEL trial, conducted by the Institut Cardiovasculaire Paris Sud, examined 238 patients. Half of the patients received coated stents, while the others received uncoated stents. One year after the procedure, 94 percent of those who received coated stents were restenosis free and had not had a major cardiac event, in comparison to 71 percent of those who received an uncoated stent.

Siroliums was approved by the Food and Drug Administration (FDA) in 1999 to prevent kidney transplant rejection.

Information from www.reuters.com

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.